Ruxolitinib for people with certain eosinophil overgrowth diseases
Treatments studied
Part of Blood & lymphatic, Digestive system clinical trials.
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your eosinophil counts have been very high for at least two tests in the last 3 months (one test must be during screening).
- Your condition needs treatment beyond steroid use (steroid intolerance, steroid not working, or relapse on other therapy).
- You have symptoms or signs of organ trouble that your study doctor believes may be from eosinophils.
- If you take steroids, your dose must have been steady for at least 28 days before starting the study drug.
- Your general health/strength must be good enough (ECOG 3 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
This Phase 2 study tests ruxolitinib (a targeted medicine) in people with essential thrombocythemia or polycythemia vera who still have troublesome symptoms. It aims to see whether it can reduce symptoms by changing disease activity and blood-related inflammation.
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
This Phase 2 study tests ruxolitinib, a targeted medicine, to improve outcomes in T-cell large granular lymphocytic leukemia (T-LGLL). It is for people whose disease is causing symptoms or who have already tried other treatment, with specific blood, infection, and medication requirements.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Hear when a new Blasts More Than 5 Percent of Bone Marrow Nucleated Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.